前列腺癌诊断时的骨折风险及风险因素评估
本研究基于美国整合医疗系统2010-2022年新诊断前列腺癌的50-89岁男性,计算FRAX十年髋部及主要骨质疏松性骨折风险。结果显示11.6%的患者10年髋部骨折风险≥3%,随年龄增长而升高,且存在种族差异,提示诊断时需评估骨骼健康。
要点
- 诊断时11.6%患者10年髋部骨折风险≥3%,≥65岁者达20.5%。
- 风险分布存在种族差异,白人最高,黑人最低。
- 高龄是主要风险因素,80-89岁男性风险极高。
核心结论
- 每9名前列腺癌患者中1名诊断时计算髋部骨折高风险,≥65岁者增至每5名中1名。
- 真实世界人群数据强调老年前列腺癌患者骨骼健康评估的重要性。
研究设计与样本
- 回顾性队列研究,纳入2010-2022年美国整合医疗系统新诊断前列腺癌的50-89岁男性25413例。
- 从电子健康记录获取FRAX变量(人口学、吸烟、既往骨折、类风湿关节炎、近期糖皮质激素、BMI)及其他风险因素(糖尿病、低25OH维生素D)。
- 使用美国FRAX(种族/民族特异性,不含骨密度)计算10年髋部(10yHIP)和主要骨质疏松性骨折(10yMOF)风险,并评估去除种族校准后的评分。
主要发现
- 总体中位年龄66.1±8.1岁;87.5%为局部或局部晚期,3.4%淋巴结阳性,9.1%转移;7.2%吸烟,20.4%糖尿病,6.4%既往骨折。
- 0.2%患者10yMOF≥20%;11.6%患者10yHIP≥3%,白人15.5%、亚裔/太平洋岛民7.3%、西班牙裔4.8%、黑人1.4%。
- 去除种族校准后,高风险比例变为亚裔/太平洋岛民14.9%、西班牙裔10.9%、黑人8.1%。
- 年龄是主要风险因素:≥65岁男性20.5%有10yHIP≥3%,80-89岁组达87.3%。
关键数值与推荐
- 高骨折风险定义为10yMOF≥20%和10yHIP≥3%。
- FRAX变量包括人口学、吸烟、既往骨折、类风湿关节炎、近期糖皮质激素治疗、BMI;其他风险因素包括糖尿病和低25OH维生素D水平。
临床怎么用
- 前列腺癌诊断时应使用FRAX等工具评估骨折风险,尤其老年患者。
- 关注种族差异对风险计算的影响,必要时考虑去除种族校准的评分。
- 对高风险患者(如10yHIP≥3%)考虑进一步骨骼健康评估和干预。
局限性
- 研究为观察性设计,可能存在未测量混杂因素。
- FRAX计算未包含骨密度,可能影响风险准确性。
- 结果基于美国整合医疗系统人群,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Older men with prostate cancer, particularly those receiving androgen deprivation therapy, have an increased fracture risk. However, contemporary studies assessing baseline fracture risk in ethnically diverse populations of men at initial prostate cancer diagnosis remain limited. METHODS: Men aged 50-89 years with newly diagnosed prostate cancer (2010-2022) in a US integrated healthcare system were identified. Demographic data, smoking, prior fracture, rheumatoid arthritis, recent glucocorticoid therapy, body mass index (FRAX variables), and other risk factors (diabetes, low 25OH-vitamin D level) were ascertained from electronic health records. Ten-year risks of hip (10yHIP) and major osteoporotic fractures (10yMOF) were calculated using the US FRAX (race/ethnicity-specific, without bone density); additional scores removed race/ethnicity calibration. High fracture risk was defined as 10yMOF ≥ 20% and 10yHIP ≥ 3%. RESULTS: Among 25,413 men with prostate cancer (mean age 66.1 ± 8.1 years; 64.8% White, 12.3% Black, 10.7% Hispanic, 11.5% Asian/Pacific Islander (PI)), 87.5%, 3.4%, and 9.1% had local or locally advanced disease, node-positive, and metastatic disease, respectively. Overall, 7.2% smoked, 20.4% had diabetes, and 6.4% had a prior fracture with demographic variation; <1% had rheumatoid arthritis or extended glucocorticoid therapy. Few (0.2%) had 10yMOF ≥ 20% but 11.6% had 10yHIP ≥ 3%, ranging from 15.5% (White), 7.3% (Asian/PI), 4.8% (Hispanic) and 1.4% (Black) and increasing to 14.9% (Asian/PI), 10.9% (Hispanic), and 8.1% (Black) without race/ethnicity calibration. Age was a major risk factor; 20.5% of men aged ≥65 years, increasing to 87.3% of men aged 80-89 years had 10yHIP ≥ 3%. Diabetes and hypovitaminosis D were especially prevalent among non-White populations. CONCLUSION: 1 in 9 men with prostate cancer had a high calculated hip fracture risk at diagnosis, increasing to 1 in 5 men aged ≥65 years, with key demographic differences. These observations in real-world populations underscore the importance of skeletal health assessment among older men with prostate cancer and evaluation of fracture risk assessment tools to inform clinical management.
引用
- Shulman MJ, Darbinian JA, Chandra M, et al. Fracture risk and fracture risk factor assessment among men at prostate cancer diagnosis. Prostate Cancer Prostatic Dis. 2026. PMID: 42869964. doi:10.1038/s41391-026-01151-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。